No Data
No Data
We Think That There Are Issues Underlying TG Therapeutics' (NASDAQ:TGTX) Earnings
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
Why TG Therapeutics Stock Was Soaring This Week
TG Therapeutics Call Volume Above Normal and Directionally Bullish
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $53